Qiu Juhui, Liu Dongjian, Yan Zaichun, Jiang Wei, Zhang Qinglei, Li Ning, Deng Wentao, Ding Kejia
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
Department of Urology, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China.
Oncol Lett. 2019 Feb;17(2):1547-1550. doi: 10.3892/ol.2018.9776. Epub 2018 Nov 28.
Efficacy and safety of sorafenib in patients with advanced renal cancer were evaluated. Seventy-four patients with advanced renal cancer treated with sorafenib + interferon from January 2010 to August 2013 were included as the observation group. Another 53 renal cancer patients treated with interferon alone were included in the control group. Clinical data of those patients were retrospectively analyzed. Treatment plan: initial dose was 400 mg, twice a day. Additionally, patients in the interferon group were treated with another 300 MU every other day. Efficacy was evaluated according to RECIST criteria, and progression-free survival (PFS), overall survival (OS), and incidence of adverse reactions were recorded. In the observation group, a median OS was 15.3 months (range, 9-60 months), and a median PFS was 8.2 months (range, 2-36 months). There were 4 cases of complete remission (CR) (5.41%), 16 cases of partial remission (PR) (21.62%), 42 cases of stable disease (SD) (56.76%), 12 cases of disease progression (16.22%), and disease control rate (DCR) was 83.78% (62 cases). In the control group, median OS time was 12.5 months (range, 8-60 months), and the median PFS time was 9.3 months (range, 2-40 months). There were 2 cases of CR (3.77%), 11 cases of PR (20.75%), 20 cases of SD (37.74%), 20 cases of disease progression (37.74%), and DCR was 62.26% (33 cases). Disease control rate in the observation group was significantly higher than that in the control group (P<0.05). Main adverse events in the groups were skin reaction, fever, diarrhea, fatigue, rash, loss of appetite, hypertension, hair loss and liver function abnormality. Sorafenib-based targeted therapy for the treatment of advanced renal cancer has a higher rate of disease control, and the adverse reactions are controllable and tolerable.
评估了索拉非尼在晚期肾癌患者中的疗效和安全性。将2010年1月至2013年8月期间接受索拉非尼+干扰素治疗的74例晚期肾癌患者纳入观察组。另将53例仅接受干扰素治疗的肾癌患者纳入对照组。对这些患者的临床资料进行回顾性分析。治疗方案：初始剂量为400mg，每日2次。此外，干扰素组患者每隔一天接受另外300MU的治疗。根据RECIST标准评估疗效，并记录无进展生存期（PFS）、总生存期（OS）和不良反应发生率。观察组的中位OS为15.3个月（范围9 - 60个月），中位PFS为8.2个月（范围2 - 36个月）。完全缓解（CR）4例（5.41%），部分缓解（PR）16例（21.62%），病情稳定（SD）42例（56.76%），疾病进展（PD）12例（16.22%），疾病控制率（DCR）为83.78%（62例）。对照组的中位OS时间为12.5个月（范围8 - 60个月），中位PFS时间为9.3个月（范围2 - 40个月）。CR 2例（3.77%），PR 11例（20.75%），SD 20例（37.74%），疾病进展20例（37.74%），DCR为62.
